Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK.

Ann Intern Med. 2006 Nov 7;145(9):660-4.

PMID:
17088579
2.

Summaries for patients. Underactive thyroid function after treatment with sunitinib for gastrointestinal cancer.

[No authors listed]

Ann Intern Med. 2006 Nov 7;145(9):I44. No abstract available.

PMID:
17088575
3.

Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.

Kappers MH, van Esch JH, Smedts FM, de Krijger RR, Eechoute K, Mathijssen RH, Sleijfer S, Leijten F, Danser AH, van den Meiracker AH, Visser TJ.

J Clin Endocrinol Metab. 2011 Oct;96(10):3087-94. doi: 10.1210/jc.2011-1172.

PMID:
21816788
4.

A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake.

Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali PG, Beck-Peccoz P, Fugazzola L.

J Clin Endocrinol Metab. 2007 Sep;92(9):3531-4.

PMID:
17595247
5.

Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume.

Sakurai K, Fukazawa H, Arihara Z, Yoshida K.

Tohoku J Exp Med. 2010 Sep;222(1):39-44.

6.

Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity.

Wong E, Rosen LS, Mulay M, Vanvugt A, Dinolfo M, Tomoda C, Sugawara M, Hershman JM.

Thyroid. 2007 Apr;17(4):351-5.

PMID:
17465866
7.

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P, Schöffski P.

Br J Cancer. 2008 Aug 5;99(3):448-54. doi: 10.1038/sj.bjc.6604497.

8.

[Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].

Fuertes Zamorano N, De Miguel Novoa MP, Molino González A, Díaz Pérez JÁ, Rojas-Marcos PM, Montañez Zorrilla MC.

Endocrinol Nutr. 2010 Dec;57(10):486-91. doi: 10.1016/j.endonu.2010.06.002. Spanish.

PMID:
20702151
9.

Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.

Sato S, Muraishi K, Tani J, Sasaki Y, Tokubuchi I, Tajiri Y, Yamada K, Suekane S, Miyajima J, Matsuoka K, Hiromatsu Y.

Endocr J. 2010;57(10):873-80.

10.

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM.

J Natl Cancer Inst. 2007 Jan 3;99(1):81-3.

PMID:
17202116
11.

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

Grossmann M, Premaratne E, Desai J, Davis ID.

Clin Endocrinol (Oxf). 2008 Oct;69(4):669-72. doi: 10.1111/j.1365-2265.2008.03253.x.

PMID:
18394019
12.

Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?

Pani F, Atzori F, Baghino G, Boi F, Tanca L, Ionta MT, Mariotti S.

Thyroid. 2015 Nov;25(11):1255-61. doi: 10.1089/thy.2015.0170.

PMID:
26414109
13.

Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?

Tassi R, Baldazzi V, Lapini A, Carini M, Mazzanti R.

Clin Genitourin Cancer. 2015 Apr;13(2):e101-5. doi: 10.1016/j.clgc.2014.08.009.

PMID:
25450040
14.

Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?

Rogiers A, Wolter P, Op de Beeck K, Thijs M, Decallonne B, Schöffski P.

Thyroid. 2010 Mar;20(3):317-22. doi: 10.1089/thy.2009.0125.

PMID:
20144039
15.

The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.

Baldazzi V, Tassi R, Lapini A, Santomaggio C, Carini M, Mazzanti R.

Urol Oncol. 2012 Sep;30(5):704-10. doi: 10.1016/j.urolonc.2010.07.015.

PMID:
20884255
16.

Sunitinib: new drug. For some gastrointestinal stromal tumours.

[No authors listed]

Prescrire Int. 2007 Aug;16(90):138-41.

PMID:
17724833
17.

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.

Nat Rev Clin Oncol. 2009 Apr;6(4):219-28. doi: 10.1038/nrclinonc.2009.4. Review.

PMID:
19333228
18.
19.

Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target.

Vetter ML, Kaul S, Iqbal N.

Endocr Pract. 2008 Jul-Aug;14(5):618-24. Review.

PMID:
18753108
20.

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.

Telli ML, Witteles RM, Fisher GA, Srinivas S.

Ann Oncol. 2008 Sep;19(9):1613-8. doi: 10.1093/annonc/mdn168.

PMID:
18436521

Supplemental Content

Support Center